How to Get Zetia (Ezetimibe) in Delaware

What Is Ezetimibe and Why Doctors Prescribe It in Delaware

Ezetimibe is a cholesterol-absorption inhibitor approved by the FDA for primary hyperlipidemia, mixed hyperlipidemia, and homozygous familial hypercholesterolemia, most often as an add-on to statin therapy when LDL-C goals are not met on a statin alone. The drug works at the brush border of the small intestine, blocking the Niemann-Pick C1-like 1 (NPC1L1) transporter and reducing the absorption of both dietary and biliary cholesterol by roughly 54% [1].

Delaware's cardiovascular disease burden mirrors the national picture. The CDC reports that heart disease remains the leading cause of death in Delaware, accounting for approximately 24% of all state deaths annually [2]. Physicians across the state routinely add ezetimibe when patients on maximally tolerated statin doses still fall short of their LDL-C target.

The ACC/AHA 2018 Guideline on the Management of Blood Cholesterol identifies ezetimibe as a first-line nonstatin option and states directly: "In patients with clinical ASCVD, if LDL-C remains 70 mg/dL or higher on maximally tolerated statin therapy, it is reasonable to add ezetimibe." [3] That guideline, published in Circulation, forms the clinical backbone of how Delaware providers approach ezetimibe prescribing today [3].

The key IMPROVE-IT trial (N=18,144) compared simvastatin 40 mg plus ezetimibe 10 mg against simvastatin 40 mg plus placebo in patients stabilized after an acute coronary syndrome. At 7 years, the combination arm achieved a mean LDL-C of 53.7 mg/dL versus 69.5 mg/dL in the monotherapy arm, and the primary composite endpoint (cardiovascular death, nonfatal MI, unstable angina requiring rehospitalization, coronary revascularization, or nonfatal stroke) occurred in 32.7% of combination patients versus 34.7% of monotherapy patients, a statistically significant absolute risk reduction of 2.0 percentage points (HR 0.936; 95% CI 0.89 to 0.99; P<0.016) [4].

How Delaware Telehealth Laws Affect Zetia Prescribing

Delaware permits telehealth prescribing for ezetimibe without requiring an in-person visit first, provided the prescribing clinician conducts a synchronous audio-video evaluation sufficient to establish a valid patient-provider relationship. Delaware Code Title 24 governs telemedicine practice and does not impose a separate "physical exam required" carve-out for lipid-lowering agents [5].

This matters for patients in rural Sussex County or those with limited transportation. A board-certified clinician can review your lipid panel results, medical history, and current medications via video, write the prescription electronically, and transmit it to a Delaware pharmacy or mail-order service the same day.

The Delaware Medical Practice Act also allows nurse practitioners and physician assistants to prescribe Schedule II through V controlled substances and non-controlled drugs like ezetimibe under their own DEA numbers (NPs) or under a collaborative agreement with a supervising physician (PAs), depending on license tier [6]. In practice, any Delaware-licensed MD, DO, NP, or PA can write a valid Zetia prescription.

A telehealth visit for ezetimibe initiation typically runs 15 to 20 minutes. The provider will ask about current statin use, prior muscle symptoms or liver enzyme elevations, and will request a recent lipid panel if one is not already on file. Visits completed before 2 p.m. on a business day commonly result in a same-day electronic prescription.

What Labs Delaware Providers Need Before Prescribing Ezetimibe

A fasting lipid panel is the foundation of any ezetimibe evaluation. Providers need baseline total cholesterol, LDL-C, HDL-C, and triglycerides to document that LDL-C is elevated and to set a measurable treatment goal [3]. Most Delaware telehealth platforms accept lab results from LabCorp, Quest Diagnostics, or any CLIA-certified Delaware draw site; results uploaded as a PDF are sufficient.

Liver function tests (AST and ALT) are recommended but not mandatory before starting ezetimibe in isolation, because the drug has a benign hepatic safety profile at 10 mg/day [1]. When ezetimibe is combined with a statin, the prescriber will typically want at least one prior ALT/AST to rule out baseline hepatic dysfunction, consistent with the ACC/AHA guideline recommendation for statin monitoring [3].

Additional workup that changes clinical decision-making:

• A thyroid-stimulating hormone (TSH) level rules out hypothyroidism as a secondary cause of elevated LDL-C, which can present with lipid panels nearly identical to primary hypercholesterolemia [7].
• Fasting glucose or HbA1c helps stratify cardiovascular risk under the ACC/AHA Pooled Cohort Equations [3].
• A creatinine and eGFR may be ordered if severe renal impairment is suspected, although ezetimibe requires no dose adjustment for renal disease [1].

Labs drawn within the preceding 12 months are generally acceptable to Delaware telehealth providers for initial evaluation. If a patient has no recent labs, most platforms can order a standing lab requisition the same day as the visit, with results available within 24 to 48 hours at most Delaware draw sites.

Step-by-Step: Getting a Zetia Prescription in Delaware

Delaware patients have three practical pathways to a first Zetia prescription.

Pathway 1: Primary Care Provider (in-person or telehealth) Schedule a lipid management visit with your Delaware-licensed primary care physician or cardiologist. Bring or upload a recent fasting lipid panel. The provider documents LDL-C above goal, selects ezetimibe per ACC/AHA guidelines, and transmits the prescription electronically [3]. This is the most straightforward route for patients already established with a Delaware provider.

Pathway 2: HealthRX or Similar Telehealth Platform Complete an online intake form covering your current medications, allergy history, and cardiovascular risk factors. Upload a lipid panel drawn within the past 12 months. A Delaware-licensed clinician reviews the intake asynchronously or schedules a 15-minute synchronous video visit. If appropriate, an electronic prescription is sent to your preferred Delaware pharmacy or mail-order service within 24 hours of visit completion.

Pathway 3: Urgent Care or Retail Clinic Several Delaware retail clinics (including those embedded in major pharmacy chains) staff NPs and PAs licensed to prescribe ezetimibe. A visit typically costs $100 to $150 without insurance and can result in an on-site prescription. This option suits patients who need a prescription quickly and have labs in hand.

Regardless of pathway, the Delaware Board of Medical Licensure and Discipline requires that the prescribing clinician document a legitimate medical purpose, the clinical indication (hyperlipidemia), the chosen dose and duration, and any monitoring plan in the medical record [6].

Delaware Pharmacy Access and Typical Wait Times

Every major pharmacy chain operating in Delaware (CVS, Walgreens, Rite Aid, ShopRite Pharmacy, and Walmart Pharmacy) stocks generic ezetimibe 10 mg. The generic has been available nationally since 2017, and retail prices at Delaware pharmacies range from approximately $15 to $40 per 30-tablet supply without insurance when GoodRx or a manufacturer coupon is applied [8].

Brand-name Zetia (Merck) carries a substantially higher list price. Merck offers a savings card that can reduce out-of-pocket cost to $5 per 30-day supply for eligible commercially insured patients [8]. Delaware Medicaid (Diamond State Health Plan and Highmark Delaware managed care organizations) covers generic ezetimibe with prior authorization on the preferred drug list.

Mail-order pharmacies ship to Delaware residential addresses without restriction. Orders placed on a Monday with a valid prescription and insurance authorization typically arrive by Thursday or Friday of the same week. Without insurance, cash-pay mail-order services (Cost Plus Drugs, for example) offer generic ezetimibe at prices competitive with or below GoodRx retail rates.

Delaware's 503A compounding pharmacies are licensed by the Delaware Board of Pharmacy and may compound ezetimibe in alternative dose forms (e.g., suspensions for patients who cannot swallow tablets, or combination capsules pairing ezetimibe with a statin that is not available as a commercial fixed-dose combination) when a prescriber documents a specific patient need [9]. The compounded product does not carry FDA approval for safety and efficacy, which means the prescriber carries additional documentation responsibility.

Delaware Medicaid and Insurance Prior Authorization

Delaware Medicaid covers ezetimibe under the hyperlipidemia therapeutic class, but requires prior authorization before the claim will be paid. The PA packet typically asks the prescriber to document:

1. The patient's most recent LDL-C value and the date of the lab draw.
2. Current or prior statin therapy, including drug name, dose, and duration of trial.
3. The clinical rationale for adding ezetimibe (LDL-C above goal despite statin, statin intolerance, or a diagnosed familial hypercholesterolemia variant).
4. ASCVD risk category per ACC/AHA 2018 guidelines [3].

Standard Delaware Medicaid PA review runs 3 to 5 business days. Urgent PA requests, where the prescriber documents immediate clinical need, must be adjudicated within 24 hours under Delaware Medicaid managed care contracts [10]. Most commercial plans in Delaware (Highmark BCBS, Aetna, UnitedHealthcare, Cigna) use similar criteria, though step-therapy requirements vary by plan year.

If a PA is denied, the prescriber has the right to submit a peer-to-peer review request within 30 days. Delaware law (Title 18, Delaware Insurance Code) mandates that insurers provide a clinical rationale for any PA denial and offer an appeals process [10]. Cardiology documentation from the IMPROVE-IT trial data and ACC/AHA guideline language frequently appears in successful PA appeals for high-risk patients [4].

How Long Until You Receive Zetia in Delaware

Most Delaware patients move from initial telehealth visit to first dose within 3 to 7 calendar days when insurance authorization is not required. The breakdown:

• Day 0: Telehealth visit completed, electronic prescription transmitted.
• Day 1: Pharmacy receives prescription, verifies insurance, adjudicates claim.
• Days 2 to 3 (retail): Prescription ready for pickup at a Delaware pharmacy.
• Days 3 to 5 (mail-order): Package shipped; delivery to most Delaware zip codes within 2 additional days.

When prior authorization is needed, add 3 to 5 business days for standard PA review, assuming the prescriber submits complete documentation on the first attempt. Patients who need the medication before PA resolves may receive a 3-day emergency supply at a Delaware retail pharmacy under Delaware's emergency dispensing regulations [9].

Transferring an Existing Zetia Prescription to Delaware

A patient relocating to Delaware from another state can transfer a non-controlled prescription to any Delaware retail pharmacy. Federal law and Delaware pharmacy regulations permit one transfer of an original prescription between pharmacies of different chains; most major chains allow unlimited transfers between same-chain locations [9].

To transfer, call or visit the new Delaware pharmacy and provide the original pharmacy's name, phone number, and prescription number. The receiving pharmacist contacts the dispensing pharmacy directly. For ezetimibe, which is non-controlled and filled repeatedly as a maintenance medication, a new Delaware provider visit to generate a fresh 90-day supply is often faster and simpler than chasing a transfer from an out-of-state pharmacy. Telehealth platforms can complete this visit the same day in most cases.

If the original prescription was an electronic prescription sent through a pharmacy benefit manager network, it may already be visible at your preferred Delaware pharmacy if that pharmacy participates in the same network. Checking the pharmacy app or calling ahead saves a trip.

Ezetimibe Safety Profile and Monitoring After Starting Treatment

Ezetimibe 10 mg once daily has a favorable tolerability record. In IMPROVE-IT, the rates of myopathy (0.2% vs. 0.2%), hepatic enzyme elevation exceeding three times the upper limit of normal (2.5% vs. 2.3%), and cancer (10.2% vs. 10.2%) were statistically indistinguishable between the ezetimibe-plus-simvastatin group and the placebo-plus-simvastatin group [4]. The drug itself does not cause statin-type muscle symptoms; reported myalgia in combination regimens is generally attributed to the concomitant statin.

A follow-up lipid panel 6 to 8 weeks after starting ezetimibe quantifies the LDL-C response. A typical reduction is 13 to 20% from baseline when ezetimibe is added to ongoing statin therapy [7]. If LDL-C remains above the goal established by the ACC/AHA 2018 guidelines (generally <70 mg/dL for very-high-risk ASCVD patients or <55 mg/dL for extremely-high-risk patients), the prescriber may consider escalation to a PCSK9 inhibitor such as evolocumab (Repatha) or alirocumab (Praluent) [3].

The FDA prescribing information for ezetimibe notes that co-administration with cyclosporine or fenofibrate requires monitoring because these drugs can increase ezetimibe plasma levels; co-administration with cholestyramine (a bile acid sequestrant) reduces ezetimibe absorption and the two should be separated by at least 4 hours [1].

Delaware providers following patients on ezetimibe typically schedule a 6-to-8-week lipid recheck and then annual labs once the patient is stable at goal. Telehealth platforms can order these follow-up labs remotely and review results asynchronously, allowing the full maintenance cycle to be managed without additional in-person visits.